Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04UFI
|
|||
| Former ID |
DIB002063
|
|||
| Drug Name |
ImMucin
|
|||
| Synonyms |
MUC-1 peptide vaccine (cancer), Vaxil BioTherapeutics/Hadassah Medical
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1/2 | [1] | |
| Company |
Hadassah Medical Organization
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mucin-1 (MUC1) | Target Info | . | [2] |
| WikiPathways | Hematopoietic Stem Cell Differentiation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01232712) A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol. 2015 Apr;169(1):44-56. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.